Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Warning Letters Hit Inadequate Investigations and QC Failings

This article was originally published in The Gold Sheet

Executive Summary

In recent warning letters, FDA continued to hammer manufacturers for inadequate investigation of out-of-specification results and lax oversight of manufacturing operations by quality control units.

You may also be interested in...



Enforcement Updates in Brief

Pan Drugs told FDA it would divert dirty plant’s API to India; Zhejiang Hisun reels from import alert, warning letter; Impax resolves warning letter; Polydrug and Akorn put on import alert; and TxCell outsources GMP problems away.

FDA Drug GMP Warning Letters Increase 6%, Focus on Supply Chain and Sterility Assurance in FY 2011

The number of drug GMP warning letters issued by FDA continued to climb in fiscal year 2011, with supply chain and sterility assurance issues dominating the agency’s attention. FDA is requesting a budget increase in FY 2013 to expand its inspectional presence abroad to better meet global supply chain threats, and agency officials are saying that failure to monitor contract manufacturers is a major problem shown in recent warning letters, but that failure to investigate out-of-specification results is still the No. 1 finding.

Dr. Reddy’s Gets U.S. FDA Advertising Letter, But Its Response Is Far From Generic

Despite changes to the website, the boxed warning about the risk of epidural or spinal hematomas for patients taking generic fondaparinux still receives little emphasis on a Dr. Reddy’s promotional page.

Related Content

UsernamePublicRestriction

Register

PS000613

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel